Hisamitsu Pharmaceutical Co. Reports Strong Q3 FY2025 Results with Increased Dividends

Hisamitsu Pharmaceutical Co ( (JP:4530) ) has issued an announcement.

Hisamitsu Pharmaceutical Co., Inc. reported a growth in net sales and profit attributable to owners in the third quarter of the fiscal year ending February 28, 2025. The company achieved an 8.2% increase in net sales and a 13.0% rise in profit attributable to owners compared to the previous year, although ordinary profit saw a slight decline. The financial results reflect a strong performance in the face of industry challenges, with strategic adjustments in their accounting practices. The company also announced a commemorative dividend in celebration of the 90th anniversary of its SALONPAS product, indicating a focus on rewarding stakeholders and enhancing shareholder value.

More about Hisamitsu Pharmaceutical Co

Hisamitsu Pharmaceutical Co., Inc. is a Japan-based company that operates in the pharmaceutical industry, primarily known for its development and sale of analgesic and anti-inflammatory products. The company is notable for its focus on transdermal patches and other topical treatments, with a significant market presence in Asia and expanding into global markets.

YTD Price Performance: -3.11%

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $2.03B

For a thorough assessment of 4530 stock, go to TipRanks’ Stock Analysis page.